Literature DB >> 19275586

HIV-1 mediated immune pathogenesis: spotlight on the role of viral protein R (Vpr).

Biswanath Majumder1, Narasimhan J Venkatachari, Alagarsamy Srinivasan, Velpandi Ayyavoo.   

Abstract

HIV-1 exploits the cellular machinery to replicate in the host cells by targeting a wide range of host factors at different stages of its life cycle. HIV-1 also induces detrimental effects in the infected and uninfected bystander cells resulting in dysregulation including interference in immune effector functions. The latter is specifically linked to the immune evasion strategies of the virus. In addition to the essential roles of structural proteins (Gag, Pol & Env), HIV-1 encoded auxiliary proteins such as Nef, Vif, Vpu, and Vpr through their interaction with the host cellular partners facilitate viral replication and dissemination. HIV-1 Vpr, a virion-associated molecule, has been implicated to play a role in the early events in virus life cycle. Vpr is a pleiotropic protein that exerts a range of effects including inhibition of cell proliferation, induction of apoptosis and modulation of a number of immune molecules. These functions could be in part responsible for Vpr induced immune evasion and virus replication. Appreciating this view is the genetic variation in vpr gene reflected in the form of polymorphisms at the amino acid level that may contribute to the potential CTL escape of the virus. It is likely that Vpr mediated dysregulation of host immune response contributes, in part, to the progression of disease. This review focuses on the recent advances regarding HIV-1 Vpr mediated immunopathogenesis and the mechanistic insight from in vitro and in vivo studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19275586     DOI: 10.2174/157016209787581445

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN: 1570-162X            Impact factor:   1.581


  17 in total

1.  Viral protein R upregulates expression of ULBP2 on uninfected bystander cells during HIV-1 infection of primary CD4+ T lymphocytes.

Authors:  Jonathan Richard; Tram N Q Pham; Yukihito Ishizaka; Eric A Cohen
Journal:  Virology       Date:  2013-05-31       Impact factor: 3.616

Review 2.  Nanotechnology-based approaches for the development of diagnostics, therapeutics, and vaccines.

Authors:  Alagarsamy Srinivasan; Anshu Rastogi; Velpandi Ayyavoo; Shiv Srivastava
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2014-06

Review 3.  Protein intrinsic disorder as a flexible armor and a weapon of HIV-1.

Authors:  Bin Xue; Marcin J Mizianty; Lukasz Kurgan; Vladimir N Uversky
Journal:  Cell Mol Life Sci       Date:  2011-10-28       Impact factor: 9.261

4.  Preferential CTL targeting of Gag is associated with relative viral control in long-term surviving HIV-1 infected former plasma donors from China.

Authors:  Mingming Jia; Kunxue Hong; Jianping Chen; Yuhua Ruan; Zhe Wang; Bing Su; Guoliang Ren; Xiaoqing Zhang; Zhen Liu; Quanbi Zhao; Dan Li; Hong Peng; Marcus Altfeld; Bruce D Walker; Xu G Yu; Yiming Shao
Journal:  Cell Res       Date:  2012-01-31       Impact factor: 25.617

Review 5.  Human immunodeficiency virus viral protein R as an extracellular protein in neuropathogenesis.

Authors:  Adriano Ferrucci; Michael R Nonnemacher; Brian Wigdahl
Journal:  Adv Virus Res       Date:  2011       Impact factor: 9.937

Review 6.  Limelight on two HIV/SIV accessory proteins in macrophage infection: is Vpx overshadowing Vpr?

Authors:  Diana Ayinde; Claire Maudet; Catherine Transy; Florence Margottin-Goguet
Journal:  Retrovirology       Date:  2010-04-09       Impact factor: 4.602

7.  Human immunodeficiency virus type 1 Vpr: oligomerization is an essential feature for its incorporation into virus particles.

Authors:  Narasimhan J Venkatachari; Leah A Walker; Oznur Tastan; Thien Le; Timothy M Dempsey; Yaming Li; Naveena Yanamala; Alagarsamy Srinivasan; Judith Klein-Seetharaman; Ronald C Montelaro; Velpandi Ayyavoo
Journal:  Virol J       Date:  2010-06-07       Impact factor: 4.099

8.  HIV-1 Vpr degrades the HLTF DNA translocase in T cells and macrophages.

Authors:  Hichem Lahouassa; Marie-Lise Blondot; Lise Chauveau; Ghina Chougui; Marina Morel; Marjorie Leduc; François Guillonneau; Bertha Cecilia Ramirez; Olivier Schwartz; Florence Margottin-Goguet
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-25       Impact factor: 11.205

9.  Human immunodeficiency virus type 1 Vpr polymorphisms associated with progressor and nonprogressor individuals alter Vpr-associated functions.

Authors:  Kevin Hadi; Leah A Walker; Debjani Guha; Ramachandran Murali; Simon C Watkins; Patrick Tarwater; Alagarsamy Srinivasan; Velpandi Ayyavoo
Journal:  J Gen Virol       Date:  2013-12-03       Impact factor: 3.891

10.  HIV-1 Vpr enhances PPARβ/δ-mediated transcription, increases PDK4 expression, and reduces PDC activity.

Authors:  Shashi Shrivastav; Liyan Zhang; Koji Okamoto; Hewang Lee; Claudia Lagranha; Yoshifusa Abe; Ashok Balasubramanyam; Gary D Lopaschuk; Tomoshige Kino; Jeffrey B Kopp
Journal:  Mol Endocrinol       Date:  2013-07-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.